Hormonal
Activation of Toll-Like Receptor 4 (TLR4) by endogenous ligands (saturated fatty acids) and exogenous ligands (gut-derived lipopolysaccharide) triggers pro-inflammatory signaling pathways (JNK, IKK, p38) that directly impair insulin signal transduction via inhibitory phosphorylation of insulin receptor substrate (IRS).
Insulin resistance is driven by inflammation triggered by specific dietary components and gut health. High intake of saturated fats and gut-derived endotoxins can activate immune receptors (TLR4) in your tissues, directly blocking insulin's ability to work. To improve insulin sensitivity, focus on reducing inflammatory triggers (like excessive saturated fats and processed foods that affect gut permeability) rather than just counting calories.
TLR4 contributes to the development of insulin resistance and inflammation through its activation by elevated exogenous ligands (e.g., dietary fatty acids and enteric lipopolysaccharide) and endogenous ligands (e.g., free fatty acids) which are elevated in obese states. TLR4, expressed in insulin target tissues, activates proinflammatory kinases JNK, IKK, and p38 that impair insulin signal transduction directly through inhibitory phosphorylation of insulin receptor substrate (IRS) on serine residues.
Why this rating
The paper is a review article synthesizing extensive literature from mouse models and human studies, though it notes conflicting interpretations regarding saturated fatty acids as direct ligands.
Source
TLR4 and Insulin Resistance
Jane J. Kim et al. · Gastroenterology Research and Practice · 2010
DOI 10.1155/2010/212563
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →